Immunotherapy has transformed the status of melanoma from a recalcitrant tumor with a high rate of relapse and death in the advanced stages to a disease that can occasionally be effectively treated and even cured. However, the new tools available to treating oncologists, immunotherapy cannot help all patients with melanoma. In particular, rare subtypes of melanoma are often just as fatal today as in the past two decades. The clinical and translational research community seeks to advance our current understanding of cancer immunology in order to offer develop new therapeutic options for patients with tumors that have failed to respond to existing options. In order to do so, we must learn from both our therapeutic successes as well as our failures. Neoadjuvant therapy has emerged as one potential platform that can advance our understanding of the tumor-immune interface, but there are others that must be explored.
The primary goal of this Research Topic is to address the critical gaps in our understanding and treatment of melanoma, particularly focusing on the limitations of current immunotherapies. Despite the significant strides made in treating melanoma, a substantial subset of patients, especially those with rare subtypes, do not respond to existing therapies. This Research Topic aims to explore innovative therapeutic strategies and deepen our understanding of the tumor-immune interface. By examining both successful and unsuccessful therapeutic approaches, we can identify new avenues for treatment. Recent advances in neoadjuvant therapy, combination therapies, and personalized medicine offer promising directions that need further exploration. This Research Topic seeks to bring together cutting-edge research and clinical insights to pave the way for more effective and inclusive melanoma treatments.
This Research Topic invites contributions that explore various aspects of melanoma therapeutics, with a particular focus on immunotherapy and its limitations. We welcome original research articles, reviews, and clinical studies that address the following themes:
• Mechanisms of resistance to current immunotherapies
• Advances in neoadjuvant therapy for melanoma
• Combination therapies involving immunotherapy and other modalities
• Personalized medicine approaches in melanoma treatment
• Biomarkers for predicting response to melanoma therapies
• Case studies on rare subtypes of melanoma and their treatment challenges
Authors are encouraged to submit manuscripts that provide new insights, propose novel therapeutic strategies, or offer comprehensive reviews of existing knowledge in these areas.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords:
Melanoma, Immunotherapy, Neoadjuvant therapy, Combination therapies, Personalized medicine, Tumor-immune interface, Therapeutic resistance, Biomarkers, Rare melanoma subtypes
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Immunotherapy has transformed the status of melanoma from a recalcitrant tumor with a high rate of relapse and death in the advanced stages to a disease that can occasionally be effectively treated and even cured. However, the new tools available to treating oncologists, immunotherapy cannot help all patients with melanoma. In particular, rare subtypes of melanoma are often just as fatal today as in the past two decades. The clinical and translational research community seeks to advance our current understanding of cancer immunology in order to offer develop new therapeutic options for patients with tumors that have failed to respond to existing options. In order to do so, we must learn from both our therapeutic successes as well as our failures. Neoadjuvant therapy has emerged as one potential platform that can advance our understanding of the tumor-immune interface, but there are others that must be explored.
The primary goal of this Research Topic is to address the critical gaps in our understanding and treatment of melanoma, particularly focusing on the limitations of current immunotherapies. Despite the significant strides made in treating melanoma, a substantial subset of patients, especially those with rare subtypes, do not respond to existing therapies. This Research Topic aims to explore innovative therapeutic strategies and deepen our understanding of the tumor-immune interface. By examining both successful and unsuccessful therapeutic approaches, we can identify new avenues for treatment. Recent advances in neoadjuvant therapy, combination therapies, and personalized medicine offer promising directions that need further exploration. This Research Topic seeks to bring together cutting-edge research and clinical insights to pave the way for more effective and inclusive melanoma treatments.
This Research Topic invites contributions that explore various aspects of melanoma therapeutics, with a particular focus on immunotherapy and its limitations. We welcome original research articles, reviews, and clinical studies that address the following themes:
• Mechanisms of resistance to current immunotherapies
• Advances in neoadjuvant therapy for melanoma
• Combination therapies involving immunotherapy and other modalities
• Personalized medicine approaches in melanoma treatment
• Biomarkers for predicting response to melanoma therapies
• Case studies on rare subtypes of melanoma and their treatment challenges
Authors are encouraged to submit manuscripts that provide new insights, propose novel therapeutic strategies, or offer comprehensive reviews of existing knowledge in these areas.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords:
Melanoma, Immunotherapy, Neoadjuvant therapy, Combination therapies, Personalized medicine, Tumor-immune interface, Therapeutic resistance, Biomarkers, Rare melanoma subtypes
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.